Pfizer Inc. $PFE Shares Sold by Allen Wealth Management LLC

Allen Wealth Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 61.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 35,655 shares of the biopharmaceutical company’s stock after selling 55,731 shares during the period. Allen Wealth Management LLC’s holdings in Pfizer were worth $908,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in PFE. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the second quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Pfizer Stock Performance

Shares of PFE stock opened at $25.17 on Monday. The stock has a market capitalization of $143.13 billion, a price-to-earnings ratio of 14.64 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company’s 50-day simple moving average is $25.18 and its 200-day simple moving average is $24.92. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. HSBC reissued a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.